Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cerilliant
Farmers Insurance
McKinsey
Federal Trade Commission
US Army
Colorcon
Teva
Mallinckrodt

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CHOLESTYRAMINE LIGHT

« Back to Dashboard

Clinical Trials for Cholestyramine Light

Trial ID Title Status Sponsor Phase Summary
NCT00000461 Harvard Atherosclerosis Reversibility Project (HARP) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 To determine by sequential coronary arteriography whether a lipid-lowering diet with and without lipid-lowering drugs could reverse coronary artery disease in normocholesterolemic patients. Also, to test whether fish oil supplements could improve human coronary atherosclerosis. Finally, to determine the effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. At least three clinical trials were conducted.
NCT00000463 Post Coronary Artery Bypass Graft (CABG) Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously.
NCT00000488 Lipid Research Clinics Coronary Primary Prevention Trial (CPPT) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine whether reduction of cholesterol by drug therapy significantly lowered the atherosclerotic coronary heart disease rate in a group of hypercholesterolemic but otherwise healthy men. Total dollars spent on the CPPT from June 1973 were $142,250,000. We do not have a year-by-year breakdown.
NCT00000594 NHLBI Type II Coronary Intervention Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine whether lowering of cholesterol with cholestyramine in a population with Type II hyperlipidemia led to a decreased rate of progression (a regression of coronary artery disease) as demonstrated by death, myocardial infarction, or progression of disease on angiography.
NCT00004266 Study of Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes at High Risk of Kidney or Heart Disease Completed Hennepin County Medical Center, Minneapolis N/A OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cholestyramine Light

Condition Name

Condition Name for Cholestyramine Light
Intervention Trials
Heart Diseases 4
Cardiovascular Diseases 4
Myocardial Ischemia 4
Coronary Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cholestyramine Light
Intervention Trials
Coronary Disease 4
Coronary Artery Disease 4
Cardiovascular Diseases 4
Hypercholesterolemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cholestyramine Light

Trials by Country

Trials by Country for Cholestyramine Light
Location Trials
Germany 8
United States 7
Netherlands 3
Brazil 3
Malaysia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cholestyramine Light
Location Trials
Kentucky 2
Florida 1
Massachusetts 1
Minnesota 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cholestyramine Light

Clinical Trial Phase

Clinical Trial Phase for Cholestyramine Light
Clinical Trial Phase Trials
Phase 4 5
Phase 3 7
Phase 2/Phase 3 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cholestyramine Light
Clinical Trial Phase Trials
Completed 20
Recruiting 4
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cholestyramine Light

Sponsor Name

Sponsor Name for Cholestyramine Light
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 4
Sanofi 3
Louisville Metabolic and Atherosclerosis Research Center 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cholestyramine Light
Sponsor Trials
Other 28
Industry 9
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fuji
Harvard Business School
Express Scripts
Johnson and Johnson
Accenture
AstraZeneca
Farmers Insurance
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.